Spruce Biosciences shares have experienced sharp upward movements and surges driven by positive regulatory and corporate milestones regarding its rare disease drug development pipeline. Significant catalysts include successful pre-BLA (Biologics License Application) meetings with the U.S. Food and Drug Administration (FDA) for its leading therapy candidate, Tralesinidase alfa (TA-ERT) targeting Sanfilippo Syndrome Type B, alignment on accelerated approval pathways, and strategic financial investments from major disease foundations.